新生血管性年龄相关性黄斑变性中中心亚区厚度变化与视力变化的相关性:VIEW 1和VIEW 2的事后分析
该研究为VIEW 1和VIEW 2随机临床试验的事后分析,纳入1815只眼,分别接受雷珠单抗0.5 mg每4周、阿柏西普2 mg每4周或阿柏西普2 mg每8周(初始3次每月注射后)治疗至52周,随后按需给药至96周。结果显示中心亚区厚度变化与最佳矫正视力变化之间呈弱相关或无相关,提示中心亚区厚度变化不应作为新生血管性年龄相关性黄斑变性视力结局的替代指标。
要点
- 在VIEW 1和VIEW 2试验中,中心亚区厚度变化与最佳矫正视力变化之间呈弱相关或无相关。
- 第96周时雷珠单抗每4周组的相关系数为-0.15(95%CI,-0.24至-0.06)。
- 线性回归分析显示中心亚区厚度变化仅解释11%的最佳矫正视力变化。
核心结论
- 中心亚区厚度变化与最佳矫正视力变化之间呈弱相关或无相关,提示中心亚区厚度变化不应作为新生血管性年龄相关性黄斑变性视力结局的替代指标。
研究设计与样本
- VIEW 1和VIEW 2随机临床试验的事后分析,共纳入1815只眼。
主要发现
- 第12、52、96周时,雷珠单抗每4周组的相关系数分别为-0.08(95%CI,-0.17至0.00)、-0.05(95%CI,-0.14至0.04)和-0.15(95%CI,-0.24至-0.06)。
- 第12、52、96周时,阿柏西普2 mg每4周组的相关系数分别为-0.13(95%CI,-0.21至-0.04)、-0.06(95%CI,-0.14至0.03)和-0.04(95%CI,-0.13至0.05)。
- 第12、52、96周时,阿柏西普2 mg每8周组的相关系数分别为-0.04(95%CI,-0.12至0.05)、-0.01(95%CI,-0.09至0.08)和-0.01(95%CI,-0.10至0.09)。
- 校正相关基线因素后,线性回归分析显示中心亚区厚度变化解释了11%的最佳矫正视力变化。
- 中心亚区厚度每减少100 μm,第52周时最佳矫正视力降低0.3个字母(P = .25),第96周时降低0.14个字母(P = .69)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Determine correlation between change in central subfield thickness (CST) and change in best-corrected visual acuity (BCVA) in neovascular age-related macular degeneration receiving anti-vascular endothelial growth factor agents. DESIGN: A post hoc analysis of VIEW 1 and 2 randomized clinical trials. METHODS: This analysis included participants randomized to ranibizumab 0.5 mg every 4 weeks (Rq4), intravitreal aflibercept injection 2 mg every 4 weeks (2q4), and intravitreal aflibercept injection 2 mg every 8 weeks after 3 monthly doses (2q8) to week 52, followed by capped as-needed (at least every 12 weeks) dosing to week 96. Relationship between changes in CST and BCVA was determined using Pearson correlation coefficient. RESULTS: Of 1815 eyes, 595 were assigned to the Rq4, 613 to 2q4, and 607 to 2q8 arms. Correlations (95% confidence intervals [CI]) at weeks 12, 52, and 96 were -0.08 (95% CI, -0.17 to 0.00), -0.05 (95% CI, -0.14 to 0.04), and -0.15 (95% CI, -0.24 to -0.06) for Rq4; -0.13 (95% CI, -0.21 to -0.04), -0.06 (95% CI, -0.14 to 0.03) and -0.04 (95% CI, -0.13 to 0.05) for 2q4, and -0.04 (95% CI, -0.12 to 0.05), -0.01 (95% CI, -0.09 to 0.08), and -0.01 (95% CI, -0.10 to 0.09) for 2q8. Linear regression analysis adjusted for relevant baseline factors showed CST changes accounted for 11% of BCVA changes. Every 100 μm decrease in CST was associated with a 0.3 letter decrease (P = .25) at week 52 and a 0.14 letter decrease (P = .69) at week 96. CONCLUSIONS: Weak or no correlation was found between changes in CST and BCVA with either agent or regimen, suggesting changes in CST should not be used as a surrogate for visual acuity outcomes in neovascular age-related macular degeneration.
引用
- Nanegrungsunk O, Gu SZ, Bressler SB, et al. Correlation of Change in Central Subfield Thickness and Change in Visual Acuity in Neovascular AMD: Post Hoc Analysis of VIEW 1 and 2. Am J Ophthalmol. 2021. PMID: 34848169. doi:10.1016/j.ajo.2021.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。